FCN-338 is under clinical development by Fochon Pharmaceutical and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FCN-338’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FCN-338 overview
FCN-338 is under development for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), relapsed or refractory diffuse large B-cell lymphoma, folicular lymphoma, acute lymphoblastic leukemia (ALL), Mantle Cell Lymphoma, systemic light chain amyloidosis (primary systemic amyloidosis), relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) and other B-cell lymphomas. The drug candidate is a small molecule and administered through oral route in the form of tablet. It acts by targeting B-cell lymphoma 2 (Bcl-2).
Fochon Pharmaceutical overview
Chongqing Fochon Pharmaceutical Co., Ltd. is engaged in the research and development of chemical drugs.
For a complete picture of FCN-338’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
